Predictive Value of PRECISE DAPT Score in STEMI Patients After Primary PCI
Launched by ASSIUT UNIVERSITY · Sep 9, 2020
Trial Information
Current as of May 20, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a scoring system called the PRECISE DAPT score to see how well it can predict complications in patients who have had a type of heart attack known as ST-segment Elevation Myocardial Infarction (STEMI). After receiving a special procedure called primary percutaneous coronary intervention (PPCI) to open blocked arteries, researchers want to find out if the PRECISE DAPT score can help identify patients at risk for slower blood flow in the heart and other serious heart-related problems shortly after the procedure.
To participate in this trial, you must be between 18 and 75 years old and have been diagnosed with STEMI within 12 hours of your symptoms starting. You also need to have undergone PPCI at a specific hospital. However, if you have certain conditions, like having a serious heart issue called cardiogenic shock, or if you've had your heart attack too long before treatment, you won't be eligible. If you join the study, you will help researchers understand how to better predict and manage risks in patients recovering from STEMI, potentially leading to improved care in the future.
Gender
ALL
Eligibility criteria
- • Inclusion Criteria:1.Subjects diagnosed as STEMI accordind to fourth universal definition with age range from 18 to 75 years underwent PPCI at cardiology hospital assiut university hospital.\[11\].
- • 2..Patients elegable for PPCI with STEMI within 12 h of symptom onset, provided it can be performed expeditiously (i.e. 120 min from STEMI diagnosis)\[12\]
- • -
- • Exclusion Criteria:1-late presentation with STEMI more than 12 hr \& door to ballon more than 120 min including rescue PCI .
- • 2- cardiogenic shock 3-Patients known to have autoimmune disease (e.g vasculitis ) 4- platelate count less than 100000 IU . 5- prothrombin concentration less than 60% 6- Patients taking triple anti thrombotics .
- • -
About Assiut University
Assiut University, a prominent academic institution located in Egypt, is dedicated to advancing medical research and clinical trials that enhance healthcare outcomes. With a strong emphasis on innovation and collaboration, the university engages in a wide array of clinical studies across various disciplines, aiming to contribute valuable insights into disease prevention, diagnosis, and treatment. Assiut University's commitment to ethical research practices and rigorous scientific methodology ensures the integrity and reliability of its clinical trials, ultimately benefiting both the local community and the global medical landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Aly Mohamed, Lecturer
Principal Investigator
Assiut University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials